BioDelivery Sciences International Inc. (NASDAQ:BDSI) was down 3.2% during mid-day trading on Monday . The stock traded as low as $2.38 and last traded at $2.39, with a volume of 711,377 shares traded. The stock had previously closed at $2.47.

Several equities research analysts have issued reports on BDSI shares. Zacks Investment Research raised BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research note on Tuesday, July 5th. FBR & Co reaffirmed a “buy” rating on shares of BioDelivery Sciences International in a research note on Thursday, May 12th. Janney Montgomery Scott reaffirmed a “hold” rating and issued a $4.00 price objective on shares of BioDelivery Sciences International in a research note on Tuesday, July 12th. Cantor Fitzgerald reaffirmed a “hold” rating on shares of BioDelivery Sciences International in a research note on Saturday, July 9th. Finally, Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $4.00 price objective (down from $6.00) on shares of BioDelivery Sciences International in a research note on Thursday, May 12th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $8.25.

The company’s market capitalization is $128.09 million. The stock’s 50-day moving average price is $2.43 and its 200-day moving average price is $3.00.

An institutional investor recently raised its position in BioDelivery Sciences International stock. Bank of Montreal Can boosted its position in BioDelivery Sciences International Inc. (NASDAQ:BDSI) by 3.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 829,056 shares of the specialty pharmaceutical company’s stock after buying an additional 28,838 shares during the period. Bank of Montreal Can owned 1.57% of BioDelivery Sciences International worth $3,971,000 as of its most recent filing with the SEC.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.